𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms

✍ Scribed by James M. Russell; Risa Weisberg; Maurizio Fava; James T. Hartford; Janelle S. Erickson; Deborah N. D'Souza

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
192 KB
Volume
25
Category
Article
ISSN
1091-4269

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Predictors of relapse in a study of dulo
Predictors of relapse in a study of duloxetine treatment for patients with generalized anxiety disorder
✍ J. Alexander Bodkin; Christer Allgulander; Pierre M. Llorca; Melissa E. Spann; D πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 112 KB πŸ‘ 1 views

## Objective Data from a relapse prevention study of duloxetine treatment for adults with generalized anxiety disorder (GAD) were examined to identify predictors of relapse. ## Methods Patients responding to 6 months of open‐label duloxetine treatment were randomized to continuation with duloxeti

Efficacy of ondansetron in the treatment
Efficacy of ondansetron in the treatment of generalized anxiety disorder
✍ A. M. Freeman III; J. R. Westphal; G. T. Norris; B. A. Roggero; P. B. Webb; K. L πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 42 KB πŸ‘ 2 views

Ondansetron is a highly selective antagonist at the 5-HT 3 subtype of serotonin (5-HT) receptors . The 5-HT 3 receptors are the only receptors whose effects are mediated through the ion channels rather than the G-protein series . Ondansetron has no appreciable affinity for other 5-HT receptor subtyp

Clinical and functional outcomes in pati
Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine
✍ David V. Sheehan; Pratap R. Chokka; Renee E. Granger; Richard J. Walton; Joel Ra πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 339 KB

## Objective This post hoc analysis of a multicenter, single‐arm, open‐label trial (the Attributes of Response in Depressed Patients Switched to Treatment with Duloxetine [ARDENT] study) assessed the relationship between functional improvement in the Sheehan Disability Scale (SDS) and clinical outc